SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Carterra Inc., the world leader in enabling high-throughput biology, announced today that it has sold and shipped its first Carterra Ultra™ biosensor ...
The symposia are tailored for the drug discovery scientist. Topics will cover antibody and large molecule through small molecule discovery, including cutting-edge areas such as machine learning and AI ...
FARGO, North Dakota & SALT LAKE CITY, Utah--(BUSINESS WIRE)--Genovac, a leading contract research and manufacturing organization (CRO/CMO) that discovers, develops, and manufactures antibodies for ...
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ®, a leading ...
Ultra boasts enhanced optics, advanced microfluidics, and thermals capable of high-sensitivity measurements in an array-based format with signal-to-noise optimized for Fragment-Based Lead Discovery ...
Carterra and PerkinElmer Sign Distribution Agreement For Asia-Pacific and Oceania Region for Carterra’s High Throughput Antibody Screening and Characterization Solutions SALT LAKE CITY, Utah—December ...
At SLAS, scientists from Dragonfly Therapeutics will discuss the benefits of running the Fc gamma receptor (FcγR) binding application which is a critical component of ADCC, ADCP, and CDC and an ...
SALT LAKE CITY, UTAH, USA (January 14, 2020) – Carterra ® Inc., the world leader in high-throughput antibody screening and characterization, has closed a $6M round of financing led by Ballast Point ...
Presentations will be delivered by experts from a wide variety of leading research groups including Pfizer, GSK, and Bio-Techne, along with co-hosts IPA, ACROBiosystems, and Curia. The symposia are ...
SALT LAKE CITY, Jan. 14, 2020 /PRNewswire-PRWeb/ -- Carterra® Inc., the world leader in high-throughput antibody screening and characterization, has closed a $6M round of financing led by Ballast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results